[1] 郑莉.2D-STI联合ECG在急性心肌梗死患者中的评估分析[J].江西医药,2021,56(11):2074-2076,2079. [2] 郝星,卢钦炳.超敏肌钙蛋白Ⅰ检测对急性心肌梗死的早期预测价值探讨[J].江西医药,2019,54(12):1559-1560,1566. [3] 鲍帅,尤淑玲,李晓鲁.心肌梗死炎性标志物的研究进展[J].现代医药卫生,2021,37(18):3118-3122. [4] 王文平,张永明,丁晓洁,等,邓大同.中性粒细胞与淋巴细胞比值和胆红素与2型糖尿病周围血管病变的相关性研究[J].临床和实验医学杂志,2021,20(3):286-289. [5] 中国医师协会胸痛专业委员会,中华心血管病杂志(网络版)编辑委员会,急性心肌梗死后心室重构防治专家共识起草组.急性心肌梗死后心室重构防治专家共识[J]. 中华心血管病杂志(网络版),2020,3(1):1-7. [6] BahrehmandM,SadeghiE,ShafieeA,et al. Predictors of delayed and no-reflow as recognized with Thrombolysis in Myocardial Infarction [TIMI]flow grade following Primary Percutaneous Coronary Angioplasty[J]. JMed Life,2019,8(Spec Iss 3):59-65. [7] 何耀华.血清CRP、IL-18水平与急性心肌梗死患者PCI治疗效果的相关性[J].河南医学研究,2021,30(36):6772-6774. [8] 张文婷,白雪琴,李方江,等.炎症因子水平及GRACE评分评估经皮冠状动脉介入术治疗急性心肌梗死患者预后的价值[J].中国分子心脏病学杂志,2021,21(4):4051-4055. [9] 张文婷,李方江,要彤,等.血清hs-CRP、ADAMTS-1、Lp-PLA2及GRACE评分、fQRS对急诊PCI后AMI患者预后的预测价值[J].山东医药,2021,61(23):47-50. [10] 陈秀,刘小熊,夏豪.中性粒细胞在心肌梗死中的作用研究进展[J].中国心血管杂志,2020,25(4):389-392. [11] 宋欢,李佳.中性粒细胞和淋巴细胞比值与急性心肌梗死相关性研究进展[J].心血管病学进展,2019,40(2):257-259. [12] 肖园园,樊仲国,王芳,等.中性粒细胞/淋巴细胞比值及平均血小板体积与STEMI患者临床结局及预后的关系[J].临床心血管病杂志,2019,35(7):604-608. [13] 王楠,郑迪,宋毓清,等.外周血中性粒细胞与淋巴细胞比值与急性心肌梗死病情及预后的关系[J].内科理论与实践,2020,15(6):369-374. [14] Akboga M K, Canpolat U, Yuksel M, et al.Platelet tolymphocyte ratio as a novel indicator of inflammation is correlatedwiththe severity of metabolic syndrome: a single center large-scale study[J]. Platelets, 2019, 27(2): 1-6. [15] Temiz A, Gazi E, GungoR, et al. Platelet/lymphocyte ratioand risk of in-hospital mortality in patients with ST-elevatedmyocardial infarction[J]. Med Sci Monit, 2020, 20(233): 660-665. [16] Sia C,Leow AS, Tan BY, et al.The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predict left ventricular thrombus resolution in acute myocardial infarction without percutaneous coronary intervention[J].Thromb Res,2020,194:16-20. |